
News|Articles|July 30, 2007
BREAKING NEWS: FDA Advisers Recommend Diabetes Drug Stay on Market
Author(s)Peggy Peck
Gaithersburg, Md. -- By a vote of 20 to three a group of FDA advisers found evidence that rosiglitazone (Avandia), the popular oral anti-diabetes drug, increases the risk of myocardial infarction. But the same advisers said the drug should stay on the market.
Advertisement
GAITHERSBURG, Md. July 30 -- By a vote of 20 to three a group of FDA advisers found evidence that rosiglitazone (Avandia), the popular oral anti-diabetes drug, increases the risk of myocardial infarction. But the same advisers said the drug should stay on the market.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Weekly Dose Podcast: Needle-Free Epinephrine, Pediatric Atopic Dermatitis Gains, Smarter Dementia Screening, Teen Depression Treatment, and Oral PCSK9 Data
2
Adjunctive Lumateperone Nearly Doubles Remission Rates at 6 Weeks in Adults With Major Depressive Disorder
3
Migraine Risk Rises With Unexpectedness of Daily Experiences: Daily Dose
4
Psychiatry in 2026: Emerging Therapies and Why Sleep Is Moving Up the Priority List
5





















































































































































































































































































































